Connect Biopharma Holdings (CNTB) Capital Expenditures (2024 - 2026)

Connect Biopharma Holdings has disclosed Capital Expenditures across 3 years of filings, most recently posting -$1000.0 for Q2 2026.

• In Q2 2026, Capital Expenditures fell 100.33% year-over-year to -$1000.0; the TTM figure through Jun 2026 stood at $218000.0 (down 74.17% YoY), while the FY2025 annual figure was $605000.0, down 19.33% from the prior year.
• Capital Expenditures came in at -$1000.0 for Q2 2026 at Connect Biopharma Holdings, up from -$2000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $313000.0 in Q4 2024 to a low of -$2000.0 in Q1 2026.
• Average Capital Expenditures over 3 years is $135200.0, with a median of $114000.0 recorded in 2024.
• Year-over-year, Capital Expenditures surged 8000.0% in 2025 and tumbled 102.47% in 2026.
• Over 3 years, Capital Expenditures stood at $313000.0 in 2024, then tumbled by 40.26% to $187000.0 in 2025, then plunged by 100.53% to -$1000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$1000.0 in Q2 2026, -$2000.0 in Q1 2026, and $187000.0 in Q4 2025.